Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003810 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003810: Completed Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
NCT00003810 is a Phase 2 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003810, a Phase 2 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more that one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and docetaxel in treating patients who have locally advanced or metastatic cancer of the pancreas.
Interventions
- DRUG docetaxel
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08-11 |
| Phase | Phase 2 |
What the finished NCT00003810 record still lists
NCT00003810 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00003810 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003810 about?
NCT00003810 is a clinical study titled "Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more that one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and docetaxel in treating patients who have loc...
What is the current status of trial NCT00003810?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-08-11.
What interventions are being tested in trial NCT00003810?
The interventions under investigation include: docetaxel (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003810?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI